LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is advancing its first-in-class PP2A inhibitor, LB-100, and will present at the Spartan Capital Investor Conference 2025, highlighting its potential in cancer therapy [1][2]. Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly targeting new avenues for cancer drug development [3]. - The lead compound, LB-100, has shown to be well-tolerated in cancer patients and has the potential to enhance the effectiveness of existing chemotherapies and immunotherapies [3][4]. Product Development - LB-100 is part of a novel approach in cancer biology known as activation lethality, which is aimed at creating a new treatment paradigm [4]. - Clinical trials for LB-100 are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [4].